Osiris Therapeutics has been given a green light by the FDA to start a Phase II trial of Prochymal--a formulation of adult stem cells--for heart attack victims. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/prochymal-demonstrates-lasting-benefit-heart-attack-patients-osiris-receives-fda-clea